US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

2.02

+0.01000.50%

Volume:102.20K

Turnover:203.69K

Market Cap:128.43M

PE:-3.72

High:2.03

Open:2.01

Low:1.98

Close:2.01

52wk High:3.43

52wk Low:0.4100

Shares:63.58M

Float Shares:39.66M

Volume Ratio:2.66

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5428

EPS(LYR):-0.6272

ROE:-161.39%

ROA:-58.43%

PB:7.05

PE(LYR):-3.22

Loading ...

Overview Company News Filings

Tuhura Biosciences Files Investigational New Drug Application for Evaluation of the Tbs-2025 Vista Inhibiting Antibody in Molecularly Defined Subsets of Aml and Other Blood Related Cancers

THOMSON REUTERS

Tuhura Biosciences draws $1.7 million from Parkview $50 million credit facility

Tuhura Biosciences releases investor presentation on overcoming cancer immunotherapy resistance

Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks

TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary

TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate

Benzinga Earnings

TuHURA Biosciences secures $50 million credit facility, royalty deal extends cash runway into 2028

Tuhura Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS

Press Release: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Inc expected to post a loss of 11 cents a share - Earnings Preview

TuHURA Biosciences CEO participates in H.C. Wainwright BioConnect fireside chat

TuHURA Biosciences files amended 8-K with pro forma Kineta merger financials

TuHURA Biosciences Initiated at Market Outperform by Citizens

TuHURA Biosciences initiated with an Outperform at Citizens

Tuhura Biosciences Inc - Credit Facility Expected to Fund Ifx-2.0 Phase 3 and Tbs-2025 Milestones

THOMSON REUTERS

Tuhura Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway Into 2028

THOMSON REUTERS

Press Release: TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

TuHURA Biosciences initiated with a Buy at Rodman & Renshaw

BRIEF-Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.

Tuhura Biosciences Inc - Enters at the Market Offering Agreement With H.c. Wainwright & Co. - SEC Filing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/HURA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HURA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","market":"US","secType":"STK","nameCN":"TuHURA Biosciences, Inc.","latestPrice":2.02,"timestamp":1789051035733,"preClose":2.01,"halted":0,"volume":102203,"delay":0,"changeRate":0.004975124378109568,"floatShares":39657200,"shares":63578528,"eps":-0.542788,"marketStatus":"Trading","change":0.01,"latestTime":"09-10 10:38:11 EDT","open":2.01,"high":2.03,"low":1.98,"amount":203691.60103,"amplitude":0.024876,"askPrice":2.03,"askSize":200,"bidPrice":2.02,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.542788,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789070400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":2.01,"preHourTrading":{"tag":"盘前","latestPrice":2.06,"preClose":2.01,"latestTime":"08:29 EDT","volume":3,"amount":6.18,"timestamp":1789043353727,"change":0.05,"changeRate":0.024876,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.06,"preClose":2.01,"latestTime":"19:47 EDT","volume":6443,"amount":13040.9902,"timestamp":1788997629863,"change":0.05,"changeRate":0.024876,"amplitude":0.024876},"volumeRatio":2.661981},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HURA\",,,,,undefined,":{"symbol":"HURA","floatShares":39657200,"roa":"-58.43%","roe":"-161.39%","lyrEps":-0.627208,"volumeRatio":2.661981,"shares":63578528,"dividePrice":0,"high":2.03,"amplitude":0.024876,"preClose":2.01,"low":1.98,"week52Low":0.41,"pbRate":"7.05","week52High":3.43,"institutionHeld":0,"latestPrice":2.02,"eps":-0.542788,"divideRate":0,"volume":102203,"delay":0,"ttmEps":-0.542788,"open":2.01,"prevYearClose":0.7567,"prevWeekClose":2.14,"prevMonthClose":2.13,"prevQuarterClose":2.34,"fiveDayClose":2.09,"twentyDayClose":2.34,"sixtyDayClose":2.27},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HURA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"HURA","fiscalQuarterEnding":"2026/06","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2026-05-15","symbol":"HURA","fiscalQuarterEnding":"2026/03","expectedEps":-0.11,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2026-03-31","symbol":"HURA","fiscalQuarterEnding":"2025/12","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"post","actualEps":-0.13},{"market":"US","date":"2025-11-14","symbol":"HURA","fiscalQuarterEnding":"2025/09","expectedEps":-0.15,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"pre","actualEps":-0.14},{"market":"US","date":"2025-08-14","symbol":"HURA","fiscalQuarterEnding":"2025/06","expectedEps":-0.14,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.21}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HURA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HURA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1777348800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HURA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HURA","date":"2026-09-09","current":-3.721527,"percent":0.698276,"low":-15.284879,"twenty":-7.657339,"median":-4.776041,"eighty":-4.038845,"high":-0.912265,"avg":-5.499063,"sd":2.644861,"marketCap":135100428},"quantilePoints":[{"date":"2024-10-31","current":-8.730961,"twenty":-7.999797,"median":-7.383325,"eighty":-6.996296,"marketCap":255964076},{"date":"2024-11-08","current":-7.555364,"twenty":-8.206244,"median":-7.555364,"eighty":-7.208419,"marketCap":221499291},{"date":"2024-11-15","current":-7.024911,"twenty":-7.675791,"median":-7.239959,"eighty":-7.070789,"marketCap":205948107},{"date":"2024-11-22","current":-7.665321,"twenty":-7.599347,"median":-7.225623,"eighty":-6.910219,"marketCap":140801257},{"date":"2024-11-29","current":-15.010301,"twenty":-7.933971,"median":-7.512354,"eighty":-7.036381,"marketCap":275718282},{"date":"2024-12-06","current":-13.866223,"twenty":-11.098214,"median":-7.555364,"eighty":-7.065054,"marketCap":254703169},{"date":"2024-12-13","current":-12.310277,"twenty":-13.486389,"median":-7.688203,"eighty":-7.082258,"marketCap":226122615},{"date":"2024-12-20","current":-9.152622,"twenty":-13.106555,"median":-8.294564,"eighty":-7.105196,"marketCap":168120904},{"date":"2024-12-27","current":-10.411108,"twenty":-12.712992,"median":-8.730961,"eighty":-7.156808,"marketCap":191237528},{"date":"2025-01-03","current":-9.404319,"twenty":-12.676382,"median":-9.175503,"eighty":-7.225623,"marketCap":172744228},{"date":"2025-01-10","current":-9.541609,"twenty":-12.383498,"median":-9.381438,"eighty":-7.248561,"marketCap":175266042},{"date":"2025-01-17","current":-10.822976,"twenty":-11.486541,"median":-9.518727,"eighty":-7.460742,"marketCap":198802968},{"date":"2025-01-24","current":-10.571279,"twenty":-11.170776,"median":-9.724661,"eighty":-7.521761,"marketCap":194179644},{"date":"2025-01-31","current":-11.325839,"twenty":-11.2987,"median":-9.861951,"eighty":-7.544431,"marketCap":208039858},{"date":"2025-02-07","current":-10.266919,"twenty":-11.2987,"median":-10.022121,"eighty":-7.555364,"marketCap":188588977},{"date":"2025-02-14","current":-10.552406,"twenty":-11.252498,"median":-10.136529,"eighty":-7.621338,"marketCap":193832969},{"date":"2025-02-21","current":-7.603262,"twenty":-11.206135,"median":-9.999239,"eighty":-7.574523,"marketCap":139661309},{"date":"2025-02-28","current":-5.806127,"twenty":-11.137841,"median":-9.861951,"eighty":-7.518625,"marketCap":106650454},{"date":"2025-03-07","current":-4.700198,"twenty":-11.042639,"median":-9.689249,"eighty":-7.174012,"marketCap":86336082},{"date":"2025-03-14","current":-4.561957,"twenty":-10.951113,"median":-9.541609,"eighty":-7.036381,"marketCap":83796785},{"date":"2025-03-21","current":-9.216075,"twenty":-10.928231,"median":-9.438641,"eighty":-6.704264,"marketCap":169286436},{"date":"2025-03-28","current":-8.340548,"twenty":-10.90535,"median":-9.216075,"eighty":-6.852872,"marketCap":153204224},{"date":"2025-04-04","current":-6.636447,"twenty":-10.864163,"median":-9.011547,"eighty":-6.704264,"marketCap":143893470},{"date":"2025-04-11","current":-7.796363,"twenty":-10.722297,"median":-8.730961,"eighty":-6.759947,"marketCap":169043136},{"date":"2025-04-17","current":-8.340296,"twenty":-10.567504,"median":-8.501461,"eighty":-6.795924,"marketCap":180836843},{"date":"2025-04-25","current":-8.521606,"twenty":-10.542452,"median":-8.46117,"eighty":-6.852364,"marketCap":184768079},{"date":"2025-05-02","current":-7.8568,"twenty":-10.498764,"median":-8.409668,"eighty":-7.030646,"marketCap":170353548},{"date":"2025-05-09","current":-7.917237,"twenty":-10.46885,"median":-8.350494,"eighty":-7.05932,"marketCap":171663960},{"date":"2025-05-16","current":-7.735926,"twenty":-10.401955,"median":-8.271427,"eighty":-7.082258,"marketCap":167732724},{"date":"2025-05-23","current":-5.593729,"twenty":-10.356677,"median":-8.259713,"eighty":-7.009861,"marketCap":131477994},{"date":"2025-05-30","current":-5.909654,"twenty":-10.322004,"median":-8.210864,"eighty":-6.792598,"marketCap":138903659},{"date":"2025-06-06","current":-5.370723,"twenty":-10.312959,"median":-8.038111,"eighty":-6.609295,"marketCap":126236344},{"date":"2025-06-13","current":-4.86896,"twenty":-10.273819,"median":-7.961523,"eighty":-5.965405,"marketCap":114442640},{"date":"2025-06-20","current":-5.01763,"twenty":-10.268299,"median":-7.907165,"eighty":-5.77585,"marketCap":117937071},{"date":"2025-06-27","current":-4.255694,"twenty":-10.254133,"median":-7.8568,"eighty":-5.590128,"marketCap":100028109},{"date":"2025-07-03","current":-4.911411,"twenty":-10.238281,"median":-7.856432,"eighty":-5.456208,"marketCap":115440443},{"date":"2025-07-11","current":-4.990628,"twenty":-10.201312,"median":-7.766145,"eighty":-5.256797,"marketCap":117302386},{"date":"2025-07-18","current":-5.010432,"twenty":-10.182292,"median":-7.688203,"eighty":-5.039996,"marketCap":117767871},{"date":"2025-07-25","current":-5.624358,"twenty":-10.127376,"median":-7.668851,"eighty":-5.052895,"marketCap":132197927},{"date":"2025-08-01","current":-4.911411,"twenty":-10.049579,"median":-7.615053,"eighty":-5.052895,"marketCap":115440443},{"date":"2025-08-08","current":-4.812391,"twenty":-9.994663,"median":-7.555364,"eighty":-5.037142,"marketCap":113113015},{"date":"2025-08-15","current":-4.975285,"twenty":-9.907714,"median":-7.528032,"eighty":-5.017728,"marketCap":138129515},{"date":"2025-08-22","current":-5.245681,"twenty":-9.861951,"median":-7.477167,"eighty":-5.037142,"marketCap":145636554},{"date":"2025-08-29","current":-5.065417,"twenty":-9.847676,"median":-7.326779,"eighty":-5.052895,"marketCap":140631862},{"date":"2025-09-05","current":-4.560678,"twenty":-9.79276,"median":-7.254296,"eighty":-5.013311,"marketCap":126618722},{"date":"2025-09-12","current":-4.668836,"twenty":-9.696332,"median":-7.110931,"eighty":-4.956091,"marketCap":129621538},{"date":"2025-09-19","current":-4.65081,"twenty":-9.618099,"median":-7.053585,"eighty":-4.911411,"marketCap":129121069},{"date":"2025-09-26","current":-4.416467,"twenty":-9.555338,"median":-6.959639,"eighty":-4.875184,"marketCap":122614968},{"date":"2025-10-03","current":-4.704889,"twenty":-9.532456,"median":-6.792598,"eighty":-4.824615,"marketCap":130622476},{"date":"2025-10-10","current":-4.65081,"twenty":-9.500422,"median":-6.659051,"eighty":-4.759515,"marketCap":129121069},{"date":"2025-10-17","current":-4.326335,"twenty":-9.445506,"median":-6.451252,"eighty":-4.704889,"marketCap":120112622},{"date":"2025-10-24","current":-4.019886,"twenty":-9.386014,"median":-6.151486,"eighty":-4.692197,"marketCap":111604644},{"date":"2025-10-31","current":-4.470546,"twenty":-9.301564,"median":-5.965405,"eighty":-4.668836,"marketCap":124116376},{"date":"2025-11-07","current":-4.416467,"twenty":-9.208999,"median":-5.850391,"eighty":-4.621968,"marketCap":122614968},{"date":"2025-11-14","current":-3.677385,"twenty":-9.18008,"median":-5.798151,"eighty":-4.596731,"marketCap":102095729},{"date":"2025-11-21","current":-2.774116,"twenty":-9.039762,"median":-5.662432,"eighty":-4.565822,"marketCap":81244064},{"date":"2025-11-28","current":-3.500461,"twenty":-8.84257,"median":-5.63426,"eighty":-4.556086,"marketCap":102516170},{"date":"2025-12-05","current":-3.465457,"twenty":-8.730961,"median":-5.593729,"eighty":-4.544729,"marketCap":101491008},{"date":"2025-12-12","current":-1.811489,"twenty":-8.705462,"median":-5.561421,"eighty":-4.506599,"marketCap":53052117},{"date":"2025-12-19","current":-1.552105,"twenty":-8.587093,"median":-5.505534,"eighty":-4.470546,"marketCap":45455669},{"date":"2025-12-26","current":-1.707387,"twenty":-8.521606,"median":-5.445058,"eighty":-4.45252,"marketCap":50003338},{"date":"2026-01-02","current":-1.568888,"twenty":-8.50549,"median":-5.407919,"eighty":-4.416467,"marketCap":45947208},{"date":"2026-01-09","current":-1.564327,"twenty":-8.469228,"median":-5.371294,"eighty":-4.409256,"marketCap":45813623},{"date":"2026-01-16","current":-1.57656,"twenty":-8.46117,"median":-5.317787,"eighty":-4.331172,"marketCap":46171874},{"date":"2026-01-23","current":-1.408413,"twenty":-8.46117,"median":-5.267885,"eighty":-4.319125,"marketCap":41247441},{"date":"2026-01-30","current":-1.163138,"twenty":-8.430269,"median":-5.249422,"eighty":-4.265631,"marketCap":34064204},{"date":"2026-02-06","current":-0.912265,"twenty":-8.395844,"median":-5.227655,"eighty":-4.145319,"marketCap":26717023},{"date":"2026-02-13","current":-2.881928,"twenty":-8.370916,"median":-5.188669,"eighty":-4.09774,"marketCap":84401506},{"date":"2026-02-20","current":-2.301396,"twenty":-8.352484,"median":-5.119354,"eighty":-3.87886,"marketCap":67399763},{"date":"2026-02-27","current":-3.358794,"twenty":-8.340447,"median":-5.054798,"eighty":-3.490101,"marketCap":98367222},{"date":"2026-03-06","current":-3.234394,"twenty":-8.312748,"median":-5.017712,"eighty":-3.42514,"marketCap":94723992},{"date":"2026-03-13","current":-4.063726,"twenty":-8.270771,"median":-4.990628,"eighty":-3.42514,"marketCap":119012195},{"date":"2026-03-20","current":-3.71126,"twenty":-8.265757,"median":-4.95929,"eighty":-3.463659,"marketCap":108689709},{"date":"2026-03-27","current":-4.042992,"twenty":-8.259713,"median":-4.911411,"eighty":-3.465457,"marketCap":118404990},{"date":"2026-04-02","current":-3.427302,"twenty":-8.251655,"median":-4.911411,"eighty":-3.465457,"marketCap":102997215},{"date":"2026-04-10","current":-4.146613,"twenty":-8.215999,"median":-4.888063,"eighty":-3.434334,"marketCap":124613914},{"date":"2026-04-17","current":-6.262232,"twenty":-8.188482,"median":-4.911411,"eighty":-3.463059,"marketCap":188192442},{"date":"2026-04-24","current":-4.844767,"twenty":-8.114171,"median":-4.911411,"eighty":-3.465457,"marketCap":145594829},{"date":"2026-05-01","current":-4.738986,"twenty":-8.030053,"median":-4.911411,"eighty":-3.469004,"marketCap":142415902},{"date":"2026-05-08","current":-5.077485,"twenty":-7.995389,"median":-4.911411,"eighty":-3.486647,"marketCap":152588467},{"date":"2026-05-15","current":-5.310203,"twenty":-7.976007,"median":-4.911411,"eighty":-3.500461,"marketCap":159582105},{"date":"2026-05-22","current":-4.818786,"twenty":-7.933354,"median":-4.916581,"eighty":-3.501154,"marketCap":149017115},{"date":"2026-05-29","current":-4.839379,"twenty":-7.917237,"median":-4.916581,"eighty":-3.503927,"marketCap":149653940},{"date":"2026-06-05","current":-4.509889,"twenty":-7.897092,"median":-4.911411,"eighty":-3.58686,"marketCap":139464736},{"date":"2026-06-12","current":-4.509889,"twenty":-7.897092,"median":-4.904697,"eighty":-3.677385,"marketCap":139464736},{"date":"2026-06-18","current":-4.571669,"twenty":-7.864858,"median":-4.888063,"eighty":-3.704485,"marketCap":141375212},{"date":"2026-06-26","current":-5.333613,"twenty":-7.8568,"median":-4.908236,"eighty":-3.727846,"marketCap":164937747},{"date":"2026-07-02","current":-5.04531,"twenty":-7.856579,"median":-4.901158,"eighty":-3.744433,"marketCap":156022193},{"date":"2026-07-10","current":-4.818786,"twenty":-7.844566,"median":-4.888063,"eighty":-3.771996,"marketCap":149017115},{"date":"2026-07-17","current":-4.571669,"twenty":-7.81248,"median":-4.891607,"eighty":-3.786112,"marketCap":141375212},{"date":"2026-07-24","current":-4.427517,"twenty":-7.760101,"median":-4.868044,"eighty":-3.812345,"marketCap":136917435},{"date":"2026-07-31","current":-4.468703,"twenty":-7.71981,"median":-4.860726,"eighty":-3.856706,"marketCap":138191085},{"date":"2026-08-07","current":-4.355441,"twenty":-7.692662,"median":-4.839379,"eighty":-3.914446,"marketCap":134688546},{"date":"2026-08-14","current":-4.736413,"twenty":-7.681875,"median":-4.818786,"eighty":-3.97155,"marketCap":146469814},{"date":"2026-08-21","current":-4.616534,"twenty":-7.672382,"median":-4.818786,"eighty":-4.019886,"marketCap":141375212},{"date":"2026-08-28","current":-4.432444,"twenty":-7.669558,"median":-4.813895,"eighty":-4.020835,"marketCap":135737694},{"date":"2026-09-04","current":-4.370015,"twenty":-7.66133,"median":-4.7776,"eighty":-4.030552,"marketCap":133825895},{"date":"2026-09-09","current":-4.411635,"twenty":-7.657339,"median":-4.776041,"eighty":-4.038845,"marketCap":135100428}],"updateTime":1789051088939},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HURA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643084422","title":"Tuhura Biosciences Files Investigational New Drug Application for Evaluation of the Tbs-2025 Vista Inhibiting Antibody in Molecularly Defined Subsets of Aml and Other Blood Related Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2643084422","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643084422?lang=en_us&edition=fundamental","pubTime":"2026-06-15 19:49","pubTimestamp":1781524166,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA4FLRVQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639677746","title":"Tuhura Biosciences draws $1.7 million from Parkview $50 million credit facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2639677746","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639677746?lang=en_us&edition=fundamental","pubTime":"2026-05-30 05:01","pubTimestamp":1780088472,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences entered a loan agreement with Parkview Holdings One for a revolving credit facility with up to $50 million of availability.Tuhura drew $1.7 million on May 26, 2026, marking the first borrowing under the facility.Proceeds are expected to fund general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL8F5glm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636200888","title":"Tuhura Biosciences releases investor presentation on overcoming cancer immunotherapy resistance","url":"https://stock-news.laohu8.com/highlight/detail?id=2636200888","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636200888?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:07","pubTimestamp":1779152849,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences outlined a $50 million non-equity credit facility and royalty transaction, projecting cash runway through Q1 2028.Facility terms include 5 years of interest-only payments at 12% on drawn amounts, a 10% commitment fee payable in shares at $2.66 subject to shareholder approval, a 1.5% annual cash fee.Royalty applies only to IFx-2.0 sales, described as low- to mid-single digits up to $450 million in annual sales.Pipeline updates include a VISTA-inhibiting antibody program in AML with a Phase 1b/2 start targeted for 2H 2026, alongside immune-modulating ADC proof-of-concept work with data targeted for 2H 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tuhura Biosciences Inc. published the original content used to gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDLPVVz9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636258096","title":"Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2636258096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636258096?lang=en_us&edition=fundamental","pubTime":"2026-05-17 14:01","pubTimestamp":1778997704,"startTime":"0","endTime":"0","summary":"Tuhura Biosciences, Inc. (HURA) has disclosed a new risk, in the Debt & Financing category. The analyst notes that Tuhura Biosciences, Inc.’s revol...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/leverage-covenants-and-royalty-drain-why-tuhura-biosciences-parkview-credit-deal-heightens-liquidity-and-dilution-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/leverage-covenants-and-royalty-drain-why-tuhura-biosciences-parkview-credit-deal-heightens-liquidity-and-dilution-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635536055","title":"TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635536055","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635536055?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:33","pubTimestamp":1778884390,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc reports results for the quarter ended March 31 - Earnings SummaryTuHURA Biosciences Inc HURA.OQ reported a quarterly adjusted loss of 13 cents per share for the quarter ended Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S29T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635533940","title":"TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635533940","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635533940?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:27","pubTimestamp":1778880435,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 13.33 percent increase over losses of $(0.15) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52619494/tuhura-biosciences-q1-eps-0-13-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"TuHURA Biosciences Q1 EPS $(0.13) Misses $(0.12) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058161","title":"TuHURA Biosciences secures $50 million credit facility, royalty deal extends cash runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058161","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058161?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:01","pubTimestamp":1778878871,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences entered a $50 million credit facility and royalty transaction in April 2026, extending anticipated cash runway into 2028.Facility allows drawdowns as needed to fund monthly operating expenses tied to clinical development and operations.Borrowings carry 12% annual interest on drawn amounts, paid monthly.Principal repayment due at 5-year maturity on April 21, 2031.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL9Md7Wj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635920058","title":"Tuhura Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635920058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635920058?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA114WDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058439","title":"Press Release: TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058439","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058439?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:00","pubTimestamp":1778878800,"startTime":"0","endTime":"0","summary":"TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update.\"I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a $50 million non-equity-based source of operating capital in the form of credit facility with our largest stockholder on attractive terms for the company allowing us to fund operations beyond anticipated top-line data in our lead IFx-2.0 program,\" said Dr. James Bianco, President and CEO of TuHURA Biosciences. \"With the financing optionality provided by the credit facility, we now look forward to several anticipated key upcoming milestones, including: meeting with the FDA to discuss our IND and development plan for o","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4022","IE0009354923.USD","ODD","BK4139","BK4232","HURA","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753574","title":"TuHURA Biosciences Inc  expected to post a loss of 11 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753574","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753574?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:13","pubTimestamp":1778703185,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences Inc  expected to post a loss of11cents a share - Earnings Preview TuHURA Biosciences Inc HURA.OQ HURA.O is expected to  show no change in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215696","title":"TuHURA Biosciences CEO participates in H.C. Wainwright BioConnect fireside chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215696","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215696?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585427,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences scheduled to take part in fireside chat at 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026.Session set for 2:00 pm ET in New York City.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7LwN7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632664162","title":"TuHURA Biosciences files amended 8-K with pro forma Kineta merger financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2632664162","media":"Reuters","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632664162?lang=en_us&edition=fundamental","pubTime":"2026-05-01 05:17","pubTimestamp":1777583879,"startTime":"0","endTime":"0","summary":"TuHURA filed an amended Form 8-K/A updating unaudited pro forma condensed combined financial information tied to its June 30, 2025 acquisition of Kineta under purchase accounting.Pro forma results for fiscal 2025 showed combined net loss attributable to common stockholders of $34.57 million, or $0.66 per share, on weighted-average basic and diluted shares of 52,737,089.The filing also presented estimated purchase consideration of $16.56 million, including $7.64 million of cash paid through prior exclusivity payments, loans, and advances, plus $8.92 million of share consideration.Preliminary allocation included $11.28 million of in-process R&D intangible assets and $10.74 million of goodwill.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbX3lRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630971293","title":"TuHURA Biosciences Initiated at Market Outperform by Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2630971293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630971293?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:59","pubTimestamp":1777298340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HURA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 09:59 ET (13:59 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630699933","title":"TuHURA Biosciences initiated with an Outperform at Citizens","url":"https://stock-news.laohu8.com/highlight/detail?id=2630699933","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630699933?lang=en_us&edition=fundamental","pubTime":"2026-04-27 16:45","pubTimestamp":1777279556,"startTime":"0","endTime":"0","summary":"Citizens initiated coverage of TuHURA Biosciences (HURA) with an Outperform rating and $9 price target TuHURA is a clinical-stage immuno-oncology c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-an-outperform-at-citizens-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629304364","title":"Tuhura Biosciences Inc - Credit Facility Expected to Fund Ifx-2.0 Phase 3 and Tbs-2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2629304364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629304364?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA2CZK8P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043653","title":"Tuhura Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043653?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nTUA2CZK8P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629043963","title":"Press Release: TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2629043963","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629043963?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:30","pubTimestamp":1776857400,"startTime":"0","endTime":"0","summary":"Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones. TAMPA, Fla., April 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc.  , a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company's pipeline, ongoing clinical trials, and general corporate expenses.  The lender is an affiliate of the Company's largest stockholder, K&V Investment One LLC.TuHURA's lead innate immune agonist, IFx-2.0, is designed to overcome prim","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HURA","BK4022","R","BK4139","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627845222","title":"TuHURA Biosciences initiated with a Buy at Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2627845222","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627845222?lang=en_us&edition=fundamental","pubTime":"2026-04-15 20:20","pubTimestamp":1776255648,"startTime":"0","endTime":"0","summary":"Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $7 price target The firm’s target is based on its estimate o...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-initiated-with-a-buy-at-rodman-renshaw-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626077922","title":"BRIEF-Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2626077922","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626077922?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:38","pubTimestamp":1775680730,"startTime":"0","endTime":"0","summary":"BRIEF-Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co. April 8  - TuHURA Biosciences Inc HURA.O:TUHURA BIOSCIENCES INC - ENTERS AT THE MARKET OFFERING AGREEMENT WITH H.C. WAINWRIGHT & CO. - SEC FILINGTUHURA BIOSCIENCES INC - MAY OFFER COMMON STOCK UP TO $50 MILLION AGGREGATE - SEC FILINGSource text: [ID:n0001193125-26-147748]Further company coverage: HURA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R1A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HURA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626922274","title":"Tuhura Biosciences Inc - Enters at the Market Offering Agreement With H.c. Wainwright & Co. - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2626922274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626922274?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:33","pubTimestamp":1775680439,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40R1A5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HURA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}]}}